Novo Nordisk (NVO)
(Delayed Data from NYSE)
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
BMY or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. NVO: Which Stock Is the Better Value Option?
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum
by Zacks Equity Research
Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.
Lilly (LLY) Launches Half-Priced Version of Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) offers a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.
Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.
What's in the Cards for AEterna (AEZS) This Earnings Season?
by Zacks Equity Research
AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.
Why Earnings Season Could Be Great for Novo Nordisk (NVO)
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
by Zacks Equity Research
BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.
Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide updates on the pipeline, when it reports first-quarter 2019 results on May 2.
Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
What's in Store for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
by Zacks Equity Research
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
Gilead Collaborates With Insitro to Develop NASH Therapies
by Zacks Equity Research
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
by Zacks Equity Research
Key highlights of the past week are collaborations and pipeline updates.
Gilead to Collaborate with Novo Nordisk for NASH Treatment
by Zacks Equity Research
Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
by Zacks Equity Research
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Bull of the Day: DexCom (DXCM)
by Kevin Cook
Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.